SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Fears of a Democratic sweep in the U.S. midterms dominate QQQ discussion, with traders attributing volatile Nasdaq selling to concerns about tech and AI regulation, including data-center scrutiny. Others call the reaction an overreaction because the outcome was widely expected and see the dip as a buying opportunity.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion centers on midterm election results and expectations of Democratic gains, with traders linking a possible blue wave to pressure on DJT and criticizing Trumps political influence. Some push back that results are unsettled or that midterm losses are routine, while others anticipate further selling.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs quarterly earnings beat and stronger-than-expected outlook, driven by surging AI data-center demand, are fueling a sharp post-results move and renewed optimism about growth. Traders remain divided over whether the rally can hold, with concerns about valuation, weaker cash flow and inventory, and reliance on data-center spending tempering the bullish reaction.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A rebound in semiconductor shares, supported by strong AMD and SMCI earnings and renewed optimism about AI demand, is lifting SOXL after steep recent losses. Traders are divided between viewing the move as a relief rally and warning that election uncertainty, tech-sector selling, and the funds 3x leverage could keep volatility high.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros stronger-than-expected quarterly results and raised full-year outlook, attributed to robust AI-server demand, are driving attention. Many traders view the growth as bullish, while others question whether thin margins, cash-flow pressures and lingering doubts about management justify the muted share-price reaction.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a sharp neocloud and AI-infrastructure selloff, with traders worried that a Democratic midterm sweep could bring tighter limits on data-center development; concerns about debt financing and whether AI demand will justify heavy investment are adding pressure. The community is split between expecting an oversold rebound ahead of earnings and warning that funding risks and weak sector sentiment could drive further losses.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles large stock-and-bond financing for its AI data-center buildout is driving debate: many traders worry about dilution, borrowing costs and whether AI spending will generate enough cash flow, while others see the completed raise as removing a funding overhang. The stocks rebound has prompted talk of a possible reversal or short squeeze, though skepticism about its financing and execution risks remains.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

AMDs strong results and outlook are fueling a semiconductor rebound, with traders treating them as evidence that AI-chip demand remains resilient ahead of Nvidias earnings. The optimism is tempered by election-related concerns about AI policy and by debate over whether Nvidias bounce can hold after recent selling.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

A sharp rebound after CIFRs Q3 report has traders debating whether the move is an oversold bounce or a short squeeze that can last. Bulls point to the start of AI leasing and the companys data-center pipeline, while bears focus on the revenue miss, buildout costs and financing risks.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Election uncertainty dominates discussion, with traders worried that Democratic gains could bring scrutiny of Musks companies and threaten SpaceXs government contracts; others argue its AI, Starlink, and launch businesses can withstand political shifts. The debate is fueling sharply divided views on the stocks near-term direction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sanofis European Phase 3 flu-COVID combination trial triggered a milestone payment to Novavax, while the community focuses on whether the partnership can translate into meaningful vaccine sales and recurring royalties. Bulls see the deal and the Matrix-M licensing model as support for the business, while skeptics point to weak commercial uptake, a muted share-price response, and uncertainty ahead of Q3 results.

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in EuropePR NewswireGAITHERSBURG, Md., Oct. 29, 2026 The global flu and...

Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026

Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026 Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026PR NewswireGAITHERSBURG, Md., Oct. 29, 2026 GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the...

Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know

Novavax (NVAX) concluded the recent trading session at $9.4, signifying a -3.09% move from its prior day's close.

Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?

Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors

Novavax (NVAX) concluded the recent trading session at $10.82, signifying a -3.91% move from its prior day's close.

Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know

In the most recent trading session, Novavax (NVAX) closed at $12.82, indicating a +1.26% shift from the previous trading day.

Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines

MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.

BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push 

Equity

National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.


Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>The bet is a public-private partnership among the NIH, the nonprofit Foundation for the NIH, researchers, drug and biotech companies, advocacy groups, philanthropies, and patients.</li><li>Stacey Adam, a senior clinical officer at the foundation, told the Times she hopes it will resemble the collaboration that produced COVID shots.</li><li>Cancer vaccines, unlike most other vaccines, are treatments, not preventives.</li></ul> Vaccine stocks rallied on Friday after a report on new details of a national push to speed up personalized cancer vaccines.<a class="mention" data-mention="$NVAX" data-symbol-id="NVAX" href="https://stocktwits.com/symbol/NVAX" target="_blank">Novavax</a> (NVAX) closed up about 16% near $13, Moderna (MRNA) about 14% near $225, and Vaxcyte (PCVX) about 10%. BioNTech (BNTX) was up about 5%, Merck (MRK) about 2%, and Pfizer (PFE) a little more than 2%.&nbsp;Moderna had a second tailwind: it rejoined the Nasdaq-100 before the market open. Vaxcyte was already higher this week on its own pneumococcal vaccine data. Novavax has no cancer-vaccine program but a vaccine platform, and the stock moved on sympathy buying. &nbsp;<h2 class="st-heading-2">NCI Aims To Start A Partnership In December</h2>National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nytimes.com/2026/10/09/science/cancer-vaccines-nih-big-bet.html">reported </a>on Friday. “We can place big bets on new ideas,” he said of new resources at the National Institutes of Health.The bet is a public-private partnership among the NIH, the nonprofit Foundation for the NIH, researchers, drug and biotech companies, advocacy groups, philanthropies, and patients. Stacey Adam, a senior clinical officer at the foundation, told the paper that she hopes it will resemble the collaboration that produced COVID shots.She said the program is expected to begin in December, starting with pancreatic, liver, and colorectal cancers, plus a subset of pediatric tumors. Adam’s goal is that within seven to ten years a patient could get a vaccine in a doctor’s office, faster than the eight to 15 years she said approval can take when the work is fragmented.<h2 class="st-heading-2">Merck, Moderna, And BioNTech Already Have Shots In Trials</h2>Cancer vaccines, unlike most other vaccines, are treatments, not preventives. Each is built for one patient, meant to train T cells to attack abnormal proteins found on that person’s tumor and nowhere else. Most use mRNA, a technology the newspaper noted had fallen out of favor with the Trump administration.The furthest along in cancer vaccines is Merck and Moderna’s personalized mRNA vaccine, intismeran autogene, also called V940. In a study of 1,137 people with advanced melanoma, the companies said in August that the shot plus Keytruda lengthened the time before cancers returned and before they spread.That is the only cancer-vaccine trial large enough so far to show definitive results. The full dataset is due at the ESMO meeting in Madrid on October 24, and the partners are also testing the approach in other tumors, including lung and bladder cancer.&nbsp;BioNTech is the other main public name. With Genentech, it is developing autogene cevumeran: a small pancreatic-cancer study found that seven of eight patients who responded to the vaccine were still alive after as long as six years of follow-up, against two of eight who did not respond, and a 260-patient trial began in 2023. BioNTech is also advancing separate cancer-vaccine programs, including BNT113 and BNT116.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around MRNA and NVAX was 'bullish' at the time of writing, while sentiment around BNTX, MRK and PFE was either 'bearish' or 'neutral.'While MRNA stock has added over 660% year-to-date, MRK has gained 38%. NVAX has added 90%, and BNTX has added 2%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-sets-new-52-week-high-as-nasdaq-100-reentry-meets-nih-cancer-vaccine-push/cZxGGuoRBnj">MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.

Current Price	$9.68
Prev Close	$9.53
Open	$9.56
Dividend Yield	0.00%
50-Day Moving Average	$10.49
Beta	1.58
Avg. Volume	8.63M
PE Ratio	-6.36

52-Week High	$13.39
52-Week Low	$6.20
Market Capitalization	$1.57B
EPS (Annual)	$2.54
Price to Book	-8.37
Revenue Per Employee	$1.5M

Feed

News

Sentiment

Earnings

Fundamentals

Info

NVAX Fundamentals